Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H10N7 Influenza Challenge Study
NCT05436444Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2023
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in influenza, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Rate of Mild to Moderate Influenza Disease at 9 days. Started Oct 2023; status: completed.
02
Conditions
influenza
Beyond the preview
Go deeper on NCT05436444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05436444.